Upregulation of both heme oxygenase-1 and ATPase inhibitory factor 1 renders tumoricidal activity by synthetic flavonoids via depleting cellular ATP
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Phil Jun | - |
dc.contributor.author | Shin, Iljin | - |
dc.contributor.author | Seo, Seung-Yong | - |
dc.contributor.author | Kim, Hyoungsu | - |
dc.contributor.author | Kim, Hong Pyo | - |
dc.date.available | 2020-02-28T15:46:13Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-10-15 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12199 | - |
dc.description.abstract | Heme oxygenase-1 (HO-1) and ATPase inhibitory factor (ATPIF) 1 is often overexpressed in different types of cancer cells. Chrysin is a naturally-occurring flavonoid with antioxidant potentials, but also known to promote apoptosis. We have synthesized four chrysin derivatives and found compounds 1 and 4 remarkably upregulated the expression of HO-1, a cytoprotective enzyme. A robust expression of ATPIF1 was only seen in compound 4. Upregulation of both proteins triggers cell death in hydrogen peroxide-primed cells. Ten derivatives of compound 4 were synthesized and measured the expression of HO-1 and ATPIF1. Again, upregulation of both proteins by compound 8 killed the cells via apoptosis. To gain a physiological significance, we treated the synthetic flavonoids in colon cancer cells, HT29 and HCT116 cells and confirmed that overexpression of both HO-1 and ATPIF1 was critical for tumor cell death with an impaired mitochondrial energetics. It would provide a strategy for developing selective anti-tumor candidates. (C) 2014 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.subject | CANCER-CELLS | - |
dc.subject | CHRYSIN | - |
dc.subject | EXPRESSION | - |
dc.subject | SYNTHASE | - |
dc.subject | TUMORS | - |
dc.title | Upregulation of both heme oxygenase-1 and ATPase inhibitory factor 1 renders tumoricidal activity by synthetic flavonoids via depleting cellular ATP | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000342575200015 | - |
dc.identifier.doi | 10.1016/j.bmcl.2014.08.055 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.24, no.20, pp.4845 - 4849 | - |
dc.identifier.scopusid | 2-s2.0-84908679596 | - |
dc.citation.endPage | 4849 | - |
dc.citation.startPage | 4845 | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 24 | - |
dc.citation.number | 20 | - |
dc.contributor.affiliatedAuthor | Seo, Seung-Yong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Chrysin derivatives | - |
dc.subject.keywordAuthor | Heme oxygenase | - |
dc.subject.keywordAuthor | ATPIF1 | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Energetics | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | CHRYSIN | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | SYNTHASE | - |
dc.subject.keywordPlus | TUMORS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.